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Introduction. In the quest for new effective drugs there is the push for faster ways to identify 
active lead compounds to develop and validate in drug discovery pipelines. Cell culture-based screens 
are easy to run and can be both standardized and automated to perform efficient high-throughput 
screens.  Combined with the large available compound libraries, they can be useful to identify leads. 
However, many of such leads have been found to fail in the subsequent validation steps, where system 
complexity increases, with many compounds revealing as toxic to a multicellular organism or unable to 
penetrate the target organs.   
Flies are increasingly and successfully being used for pharmacological studies (Freires et al., 
2016) as demonstrated by the highly attended Fly Pharmacology workshop at the 2018 Drosophila 
Research Conference in Philadelphia earlier this year. In this crowded venue, it emerged that there 
appears to be a substantial bias against using flies for drug discovery, which is manifested in frequent 
proposal rejections and caustic comments from reviewers. Here I will forego extensive discussion of the 
worth of Drosophila studies, as this community is well-aware of the strength of this model. However, I 
want to reflect on some of the common concerns and share our experience in hopes to encourage the 
use of flies in drug discovery and ideally to start a discussion or reflections on this topic that may help to 
strengthen grant proposals and build strategies for the success of drug discovery research in Drosophila.  
Whole-animal screens in drug discovery and development. Whole-animal screens can 
efficiently reveal toxicity and can thus eliminate many false positives at an early stage, saving time and 
expenses, remaining aware that, depending on animal model, screening and protocol administration 
used some active compounds may be missed because of improper absorption and permeability issues. 
Concerns have been raised regarding the real significance of the results in model organisms and how 
they may translate to humans. This is particularly true of the invertebrate disease models 
Coenorhabditis elegans and Drosophila melanogaster that have, however, demonstrated remarkable 
successes in pharmacological assays. Key to these achievements were the careful use of the disease 
model and proper definition of the experimental question, which are paramount in comparative and 
model organism studies. In fact, mammalian models, particularly mice where a large statistic is available, 
have yielded results that do not always translate to humans. Thus, warnings about overreliance on mice 
models have been voiced (Strange, 2016). Vertebrate models demand high maintenance costs ranging 
from about one thousand dollars per year for one mouse and 2500 dollars for a rat, to approximately 
40,000 dollars for one monkey, and are subjected to ethical concerns. Moreover, both disease 
mechanism and drug’s mechanism of action are often largely unknown and relatively intractable in 
mammalian models, reducing experimental power to little more than careful description of the 
processes. While important, descriptive knowledge scarcely contributes to mechanistic knowledge of 
the disease and drug action. In search for productive ways forward, Drosophila appears to offer key 
advantages as drug discovery model. For example, Drosophila has excellent genetic conservation, the 
equivalent of most human organs (unlike C. elegans) and has sophisticated genetic tools that can be 
used for mechanistic studies. Both disease mechanism and drug mechanism of action can be probed in 
the fly. In comparison, zebrafish, a popular vertebrate model for pharmacology, has much less 
developed genetics and is aquatic, which may impact certain studies (e.g., kidney pharmacology). 
Drosophila short life span and culture economy lends itself well to longevity studies and to monitor the 
consequences of prolonged drug administration, potentially decreasing costs of the drug discovery 
pipeline that may become prohibitive in other animals. While long-term drug response monitoring in 
complex vertebrates could in principle be implemented by investing with bold funding programs, 
current high-throughput pharmacological screens often remain brute-force approaches with low success 
rates. Therefore, in the long term it seems prudent to work towards improving efficiency of the drug 
pipeline, ideally by integrating data from interdisciplinary research on multiple systems to accelerate 
discovery. The resulting improved success rates would free up resources to tackle more diseases. 
Because these efforts have been embraced by the scientific community, there is the need for dialog and 
sharing thoughts and experiences to fully comprehend this new field with its obvious strengths and yet-
to-be-defined limitations.  
Common approaches and concerns for fly-centered drug discovery. Drug development requires 
structure-activity relationship studies, which involves experimental iterations to determine which 
positions in the molecule can be modified to optimize drug properties. For expedience, analytical 
amounts of synthetic compounds should ideally be used in this phase, which can be conveniently be 
achieved in whole-animal models using flies.   
Chronic disease appears to pose a particularly complex problem for pharmacology. Compared to 
forms of aggressive cancer, for example, chronic disease may take longer to become life-threatening and 
may require maintenance regimes with long-term drug administration. In these conditions, even slight 
toxicity may become a serious concern which reduce effective drug options, highlighting the need for 
long-term toxicological studies.  
When using flies in drug discovery, one important concern regards possible laborious drug 
administration. The insect cuticle may present a barrier to administration of certain drugs and 
microinjection has been used successfully in the quest for drugs targeting the nervous system. While 
conveniently done, microinjection is laborious and may limit high- and medium-throughput drug-
screening efforts. Other forms of administration such as spraying are also possible and can be 
automated (Pandey and Nichols, 2011). Oral administration, on the other hand, can be easily and 
qualitatively monitored by mixing the drug with food and coloring agents, the ingestion of which can be 
seen through the semi-transparent cuticle of both adults and larvae. If deemed important, a fluorescent 
compound can be added instead and used as a proxy to quantify ingested amounts. It is often feared 
that flies will reject certain drugs, but that may not be a frequent occurrence. In our experience, we 
have administered 24 different compounds of four different chemical families including peptides, 
peptide derivatives and different small-molecule drugs, used both alone and in combination. We never 
found an instance of drug rejection as determined with food-coloring-spiked mixes of food and drugs. 
Speaking with other colleagues, we can report anecdotally that drug ingestion seems to be a common 
occurrence, suggesting that drug rejection may be infrequent and possibly limited to some pungently 
smelling molecules. 
 It is likely that oral administration may require higher compound dosage compared to 
microinjection, due to in-animal drug processing and may even result in either inactivation of certain 
drugs (e.g., unmodified peptides) or even drug uptake by the yeast in which the drug is often mixed 
prior to being fed to the flies. While remedial use of yeast extract instead of whole cells may be 
attempted in the latter case, the ease of oral administration and the small scale of fly-based drug assays 
make the use of possibly higher doses of compounds much more attractive than microinjection. We 
found that dose-response of rapamycin administration to a fly model of polycystic kidney disease 
indicated an effective dose of 12.5 µM, which is nine to ten times higher than those injected into mice 
models (Gamberi et al., 2017). Albeit this particular proof-of-principle experiment only represents a 
single instance, we noticed that this concentration of orally-administered drug was within one order of 
magnitude of the doses injected into mice, which may optimistically be considered as suggestive of 
possible similar range of activity in the two systems, at least for rapamycin. Future investigations will 
likely provide more information to evaluate this possibility.  
In our experience it has always been useful to perform dose-response assays in the fly to ensure 
drug activity. Precise drug dosage on the other hand, is regarded as largely species-specific due to the 
exact aspects of physiology typical of each species. Thus, model organisms, including Drosophila, may 
occasionally guide drug dosage range, but are not considered valid guidelines a priori. In exciting new 
developments, flies have shown conservation of certain drug-binding sites (Ziehm et al., 2017) and of 
toxicological pathways (Zhou et al., 2017) corroborating the accumulating evidence for Drosophila being 
a bona fide model for drug discovery in which toxicological studies are also possible. Signs of activation 
of conserved toxicological pathways can be monitored over time via -omics approaches that can also 
simultaneously enable the basic study of how cellular pathways respond and adapt to drug treatment, 
doubling the return on investment of these types of studies.  
Conclusions. We are in the pioneering days for fly pharmacology in which healthy skepticism 
abounds, yet the accumulating evidence suggests that flies can be useful models in which to accelerate 
drug discovery, identify good-quality lead compounds and ultimately provide indications of drug efficacy 
for specific conditions. The research frontline recognizes the need to invest into validating the use of 
invertebrate models in drug discovery. Studies of global responses to chemical treatments in different 
genetic backgrounds will help to precisely define the boundaries of what is possible to achieve using fly 
models combined with clever choices of experimental questions based on basic comparative knowledge. 
Considering the current trend of successes, fly pharmacology promises to be here to stay.  
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